Cancer Drug Resistance (eBook)
XVI, 617 Seiten
Humana Press (Verlag)
978-1-59745-035-5 (ISBN)
Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.
Part I. Physiological Resistance
The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors
Mark W. Dewhirst, Yiting Cao, Benjamin Moeller, and Chuan-Yuan Li
Influence of Tumor pH on Therapeutic Response
Chang W. Song, Robert Griffin, and Heon Joo Park
Tumor Oxygenation and Treatment Response
Sarah Jane Lunt and Richard P. Hill
Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance: The Role of Evolving Interrelationships Between Cancer Cells and Host Tissues
Janusz W. Rak, Brenda Coomber, and Joanne L. Yu
PET Imaging of Response and Resistance to Cancer Therapy
David A. Mankoff and Kenneth A. Krohn
Part II: Biological Resistance
Cancer Stem Cells: Implications for Development of More Effective Therapies
Ilia Mantle, Gabriela Dontu, Suling Liu, and Max S. Wicha
Therapeutic Resistance in Leukemia
William R. Waud
Tumor Site Implantation and Animal Model Selection in Oncology
Anibal A. Arjona and Enrique Alvarez
In Vivo Resistance
Beverly A. Teicher
Characteristics of the Metastatic Phenotype: The Melanoma Experience
Vladislava O. Melnikova and Menashe Bar-Eli
The Microenvironment and Drug Resistance
Patrice J. Morin
Part III. Biochemical Resistance
Glutathione and Glutathione S-Transferases in Drug Resistance
Victoria J. Findlay, Danyelle M. Townsend, and Kenneth D. Tew
Metallothioneins in Drug Resistance
Faiyaz Notta and D. James Koropatnick
Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors
Elena Monti
New and Revised Concepts in Multidrug Resistance: Sestamibi, SNPs, Substrates, and Stem Cells
Susan E. Bates, John Deeken, Chaohong Fan, and Robert W. Robey
Cisplatin Resistance: Molecular Basis of a Multifaceted Impediment
Zahid H. Siddik
Regulation of the Cellular Pharmacology and Cytotoxicity of Cisplatin by Copper Transporters
Roohangiz Safaei and Stephen B. Howell
Resistance to Taxanes
Lee M. Greenberger and Deepak Sampath
CpG Island Methylation and Drug Resistance
Jens M. Teodoridis and Robert Brown
De Novo and Acquired Resistance to Antitumor Alkylating Agents
Lori A. Hazlehurst and William S. Dalton
Resistance to Antiangiogenic Agents
George W. Sledge, Jr., Kathy D. Miller, Bryan Schneider, and Christopher J. Sweeney
Part IV. The Role of Hormones, Growth Factors, and Oncogenes
Resistance to Antiestrogens
Clodia Osipo and Ruth M. O'Regan
Mechanisms of Glucocorticoid Actions and Resistance in Multiple Myeloma
Varsha Gandhi and Beatriz Sanchez-Vega
Herceptin Resistance
Ingrid A. Mayer and Carlos L. Arteaga
Role of TGF-b in Tumor Progression and Metastasis
Jan Pinkas and Beverly A. Teicher
p53-Based Immunotherapy of Cancer
Albert B. DeLeo
Response and Resistance to Ionizing Radiation
Paul Dent, Adly Yacoub, Michael P. Hagan, and Steven Grant
Amplification in DNA Copy Numbers as a Mechanism of Acquired Drug Resistance
M. Jim Yen, Ie-Ming Shih, Victor E. Velculescu, and Tian-Li Wang
Part V. Clinical Aspects of Resistance
Cancer Chemotherapy: Clinical Evidence for Drug Resistance
Mika A. Sovak and David R. Spriggs
Molecular Profiling in Breast Cancer: Genomic Approaches Toward Tailored Cancer Therapies
Kristin Kee and Jeffrey E. Green
Tumor Immune Escape Mechanisms
Yi Ting Koh, M. Luz García-Hernández, and W. Martin Kast
Index
| Erscheint lt. Verlag | 9.11.2007 |
|---|---|
| Reihe/Serie | Cancer Drug Discovery and Development |
| Zusatzinfo | XVI, 617 p. |
| Verlagsort | Totowa |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Suchtkrankheiten | |
| Schlagworte | angiogenesis • Cancer • Cytotoxicity • Drug • drug resistance • hormones • Imaging • immunotherapy • leukemia • melanoma • Oncogenes • pharmacology • resistance • Toxicity • Tumor |
| ISBN-10 | 1-59745-035-9 / 1597450359 |
| ISBN-13 | 978-1-59745-035-5 / 9781597450355 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 9,0 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
